ConductScience.org, home

Paper34907910

Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers.

Yarchoan M and 28 others. J Clin Invest, 2021. Cited by 109 papers, by iCite.

Cite this record

ConductScience Library. Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers. Papers, record 34907910. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34907910

Download JSON
Disease
cholangiocarcinoma144 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers.
PubMed
Journal
J Clin Invest
PubMed
Year
2021
PubMed
Publication types
Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
109
iCite
Relative citation ratio, by iCite
5.4
iCite
Revised in PubMed
2023-07-14
PubMed

Authors29

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yarchoan MMark
2Cope LLeslie
3Ruggieri ANAmanda N
4Anders RARobert A
5Noonan AMAnne M
6Goff LWLaura W
7Goyal LLipika
8Lacy JJill
9Li DDaneng
10Patel AKAnuj K
11He ARAiwu R
12Abou-Alfa GKGhassan K
13Spencer KKristen
14Kim EJEdward J
15Davis SLS Lindsey
16McRee AJAutumn J
17Kunk PRPaul R
18Goyal SSubir
19Liu YYuan
20Dennison LLauren

Source PubMed

See all 29 authorsDownload CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Biliary Tract NeoplasmsMajor topic
Aged
Antibodies, Monoclonal, Humanized
Azetidines
Disease-Free Survival
Female
Humans
Male
Middle Aged
Piperidines
Progression-Free Survival

Source PubMed

Download CSV of topics

Grants10

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
UL1 TR001863NCATS NIH HHSUnited StatesUL1TR001863PubMedNIH RePORTER
UM1 CA186712NCI NIH HHSUnited StatesUM1CA186712PubMedNIH RePORTER
P30 CA008748NCI NIH HHSUnited StatesP30CA008748PubMedNIH RePORTER
P30 CA016058NCI NIH HHSUnited StatesP30CA016058PubMedNIH RePORTER
UM1 CA186717NCI NIH HHSUnited StatesUM1CA186717PubMedNIH RePORTER
UM1 CA186691NCI NIH HHSUnited StatesUM1CA186691PubMed and NIHNIH RePORTER
K12 CA086913NCI NIH HHSUnited StatesK12CA086913PubMedNIH RePORTER
R01 CA228414NCI NIH HHSUnited StatesR01CA228414PubMed and NIHNIH RePORTER
P50 CA062924NCI NIH HHSUnited StatesP50CA062924PubMed and NIHNIH RePORTER
P30 CA006973NCI NIH HHSUnited StatesP30CA006973PubMed and NIHNIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT03201458Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder CancerDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

References40

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
131257581Targeting Treg cells in cancer immunotherapy.Eur J Immunol2019https://conductscience.org/library/papers/31257581PubMed
225436118Second-line systemic treatment for advanced cholangiocarcinoma.J Gastrointest Oncol2014https://conductscience.org/library/papers/25436118PubMed
332234665Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer.Eur J Cancer2020https://conductscience.org/library/papers/32234665PubMed
434339623Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study.Lancet Oncol2021https://conductscience.org/library/papers/34339623PubMed
524244023The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer.J Immunol2013https://conductscience.org/library/papers/24244023PubMed
632352498A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer.JAMA Oncol2020https://conductscience.org/library/papers/32352498PubMed
719395114A systems biology perspective on cholangiocellular carcinoma development: focus on MAPK-signaling and the extracellular environment.J Hepatol2009https://conductscience.org/library/papers/19395114PubMed
826742998Cancer statistics, 2016.CA Cancer J Clin2016https://conductscience.org/library/papers/26742998PubMed
928928158Characterization of the Immune Microenvironment in Hepatocellular Carcinoma.Clin Cancer Res2017https://conductscience.org/library/papers/28928158PubMed
1024769639Second-line chemotherapy in advanced biliary cancer: a systematic review.Ann Oncol2014https://conductscience.org/library/papers/24769639PubMed
1129848569Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.Clin Cancer Res2018https://conductscience.org/library/papers/29848569PubMed
1228441383The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.Br J Cancer2017https://conductscience.org/library/papers/28441383PubMed
1331003911Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.Lancet Oncol2019https://conductscience.org/library/papers/31003911PubMed
1432416072Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.Lancet Oncol2020https://conductscience.org/library/papers/32416072PubMed
1525589619The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4.Clin Cancer Res2015https://conductscience.org/library/papers/25589619PubMed
1631454426Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes.Cancer2019https://conductscience.org/library/papers/31454426PubMed
1733547983Tumor and Systemic Immunomodulatory Effects of MEK Inhibition.Curr Oncol Rep2021https://conductscience.org/library/papers/33547983PubMed
187644477A synthetic inhibitor of the mitogen-activated protein kinase cascade.Proc Natl Acad Sci U S A1995https://conductscience.org/library/papers/7644477PubMed
1930563938Binimetinib plus Gemcitabine and Cisplatin Phase I/II Trial in Patients with Advanced Biliary Cancers.Clin Cancer Res2019https://conductscience.org/library/papers/30563938PubMed
2011391522Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States.Hepatology2001https://conductscience.org/library/papers/11391522PubMed

See all 40 referencesDownload CSV of references

Cited by68

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 109 citations.

PMIDTitleJournalYearIn PapersSource
42660998Dyslipidaemia and hepatic steatosis: mechanisms and implications for lipid-lowering therapy.Nat Rev Cardiol2026https://conductscience.org/library/papers/42660998PubMed
42511572Advances in Immunotherapy for Intrahepatic Cholangiocarcinoma.Int J Mol Sci2026https://conductscience.org/library/papers/42511572PubMed
42377085A Randomized Phase II Study of Combination Atezolizumab and Varlilumab (CDX-1127) with or without Cobimetinib in Previously Treated Unresectable Biliary Tract Cancer.Clin Cancer Res2026https://conductscience.org/library/papers/42377085PubMed
42115188The multi-kinase inhibitor tinengotinib as monotherapy or combined with atezolizumab in advanced solid tumors: a phase Ib/II trial.Nat Commun2026https://conductscience.org/library/papers/42115188PubMed
42113099Exercise-induced modulation of the unfolded protein response: a therapeutic avenue for muscle wasting disorders.J Physiol Biochem2026https://conductscience.org/library/papers/42113099PubMed
42110477CAR-T cells directed toward PD-L1 demonstrate potent, antigen-specific activity against cholangiocarcinoma: A proof of concept study.Mol Ther Oncol2026https://conductscience.org/library/papers/42110477PubMed
41756323Advancing systemic therapy for biliary tract cancer: current strategies and emerging paradigms.Front Oncol2026https://conductscience.org/library/papers/41756323PubMed
41373405A Comprehensive Analysis of Novel Variations Associated with Bile Duct Cancer: Insights into Expression, Methylation, and 3D Protein Structure.Int J Mol Sci2025https://conductscience.org/library/papers/41373405PubMed
41226789Expanding Horizons in Cholangiocarcinoma: Emerging Targets Beyond FGFR2 and IDH1.Int J Mol Sci2025https://conductscience.org/library/papers/41226789PubMed
41220768Recent advancements in systemic therapy for biliary tract cancers: a literature review.J Gastrointest Oncol2025https://conductscience.org/library/papers/41220768PubMed
41206885Use of Neoadjuvant Immunotherapy in Malignant Peritoneal Mesothelioma as a Bridge to Surgical Intervention: A Case Report.Am J Case Rep2025https://conductscience.org/library/papers/41206885PubMed
41178912Global gene expression landscape of gallbladder cancer and advances in targeted therapeutic strategies.World J Clin Oncol2025https://conductscience.org/library/papers/41178912PubMed
41143064Targeting the tumor microenvironment in cholangiocarcinoma to improve immune checkpoint blockade: potential strategies and translational pre-clinical models.Clin Transl Immunology2025https://conductscience.org/library/papers/41143064PubMed
40972018Development of a murine tumor-infiltrating lymphocyte therapy model for cholangiocarcinoma.J Immunol2026https://conductscience.org/library/papers/40972018PubMed
40940908Immune-Checkpoint Inhibitors for Biliary Tract Cancer: Who Benefits and What Is Next?Cancers (Basel)2025https://conductscience.org/library/papers/40940908PubMed
40861435Immunotherapy in biliary tract cancer: reshaping the tumour microenvironment and advancing precision combination strategies.Front Immunol2025https://conductscience.org/library/papers/40861435PubMed
40830299Enhancer regulation in cancer: from epigenetics to m6A RNA modification.Arch Pharm Res2025https://conductscience.org/library/papers/40830299PubMed
40760243Efficacy and safety of targeted therapy and immune checkpoint inhibitors in patients with advanced or metastatic biliary tract cancer: a meta-analysis of and sequential analysis of trials.Hepatol Int2025https://conductscience.org/library/papers/40760243PubMed
40668526Improving the Accumulation and Solubility of Human Interferon-γ (hIFN-γ) in Escherichia coli: A Fusion Protein-Based Method and Network Pharmacology Analysis.Appl Biochem Biotechnol2025https://conductscience.org/library/papers/40668526PubMed
40590857Tumor site influences efficacy of MEKi and immunotherapy combinations in a preclinical model of cholangiocarcinoma.Hepatology2026https://conductscience.org/library/papers/40590857PubMed

See all 68 cited byDownload CSV of cited by

Genes7

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
BTLA151888PubTator's text mininghttps://conductscience.org/library/genes/151888NCBI Gene
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
FOXP350943PubTator's text mininghttps://conductscience.org/library/genes/50943NCBI Gene
LAG33902PubTator's text mininghttps://conductscience.org/library/genes/3902NCBI Gene
MAP2K75609PubTator's text mininghttps://conductscience.org/library/genes/5609NCBI Gene
VSIR64115PubTator's text mininghttps://conductscience.org/library/genes/64115NCBI Gene

Download CSV of genes

Drugs2

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
COBIMETINIBCHEMBL2146883Derived from the trial1https://conductscience.org/library/drugs/CHEMBL2146883ChEMBL
ATEZOLIZUMABCHEMBL3707227Derived from the trial1https://conductscience.org/library/drugs/CHEMBL3707227ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34907910

GET https://conductscience.org/api/papers/v1/34907910/authors?page=2